Clinical Trial

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-03.
Trial Details
NCT Number NCT07389239
Lead Sponsor University of Chicago
Conditions Ovarian Cancer, Advanced Malignant Solid Tumor
Enrollment 24 participants
Start Date 2026-06-23
Primary Completion 2031-12-10 (estimated)
Study Completion 2031-12-10 (estimated)
Updated on ClinicalTrials.gov 2026-02-20